Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant neutrophil <i>JAK2</i><sup>V617F</sup> mutation screening and <i>PRV‐1</i> expression analysis in myeloproliferative disorders and secondary polycythaemia

6 Sept 2005

Abstract excerpt

Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the JAK2 tyrosine kinase (JAK2(V617F)) in granulocyte-derived DNA and increased granulocyte polycythaemia rubra vera-1 (PRV-1) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2(V617F) and quantitative measurement of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16197445
DOI: 10.1111/j.1365-2141.2005.05743.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant neutrophil <i>JAK2</i><sup>V617F</sup> mutation screening and <i>PRV‐1</i> expression analysis in myeloproliferative disorders and secondary polycythaemiaPMID 16197445Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.Semantic proximity Read ↗

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.Semantic proximity Read ↗

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

<i>JAK2</i><sup>V617F</sup> mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceSemantic proximity Read ↗

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?Semantic proximity Read ↗

Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.Semantic proximity Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.Semantic proximity Read ↗

<i>JAK2</i> (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.